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Excessive alcohol consumption is associated with spontaneous burning pain, 
hyperalgesia and allodynia. Although acetaldehyde has been implicated in the painful 
alcoholic neuropathy, the mechanism by which the ethanol metabolite causes pain 
symptoms is unknown. Acute ethanol ingestion caused delayed mechanical allodynia in 
mice. Inhibition of alcohol dehydrogenase (ADH) or deletion of transient receptor 
potential ankyrin 1 (TRPA1), a sensor for oxidative and carbonyl stress, prevented 
allodynia. Acetaldehyde generated by ADH in both liver and Schwann cells surrounding 
nociceptors was required for TRPA1-induced mechanical allodynia. Plp1-Cre;Trpa1fl/fl 
mice with a tamoxifen-inducible specific deletion of TRPA1 in Schwann cells revealed 
that channel activation by acetaldehyde in these cells initiates a NADPH oxidase-1 
(NOX-1)-dependent production of hydrogen peroxide (H2O2) and 4-hydroxynonenal (4-
HNE), which sustains allodynia by paracrine targeting of nociceptor TRPA1. Chronic 
ethanol ingestion caused prolonged mechanical allodynia and loss of intraepidermal small 
nerve fibers in WT mice. While Trpa1-/- or Plp1-Cre;Trpa1fl/fl mice did not develop 
mechanical allodynia, they did not show any protection from the small fiber neuropathy. 
Human Schwann cells express ADH/TRPA1/NOX1 and recapitulate the proalgesic 
functions of mouse Schwann cells. TRPA1 antagonists might attenuate some symptoms 











Alcohol abuse and dependence are among the major healthcare problems in the 
world (1). The impact of alcohol abuse continues to grow due to the rising incidence of 
excessive drinking by women and young people (2). Nevertheless, the male/female ratio 
of current drinkers and heavy episodic drinkers, which is 1.7 and 2.5, respectively, 
indicate twice the prevalence in men compared to women (2). About 60% of alcoholics 
exhibit a peripheral polyneuropathy, associated with pain and dysesthesias of the lower 
extremities (3). Reduced thiamine levels (4), which cause peripheral neuropathy in 
patients with post-gastrectomy polyneuropathy or beriberi, have been reported in 
alcoholics, and have been considered responsible for the peripheral neuropathy (5, 6). 
However, the observation that painful polyneuropathy is present in alcoholics with 
normal thiamine status (6), and that the clinical and pathological features of alcoholic 
neuropathy are distinct from those associated with thiamine deficiency (7) led to the 
conclusion that alcohol exerts a direct toxic effect on peripheral nerves. However, the 
mechanism by which ethanol targets peripheral nerves to cause the painful condition 
remains unknown. 
Alcohol dehydrogenase (ADH) converts ethanol into the reactive and toxic product 
acetaldehyde, which is rapidly metabolized to acetic acid by the mitochondrial aldehyde 
dehydrogenase-2 (ALDH2) (8). Acetaldehyde is considered as the major contributor of 
the detrimental effects produced by acute and chronic alcohol consumption, including 
flushing, headache, cirrhosis and cancer (9-12). Mutations of the ADH and ALDH2 
genes, which respectively accelerate ethanol conversion to acetaldehyde and slow down 
acetaldehyde metabolism, make East Asians susceptible to alcohol-induced symptoms 
with lower rates of alcohol use (13, 14). Acetaldehyde generates advanced glycation end-
products and increases oxidative stress, which can contribute to ethanol-induced painful 
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neuropathy (15). In particular, preclinical studies and clinical evidence have implicated 
acetaldehyde in the genesis of the neuronal damage associated with ethanol consumption 
(3). However, the pathways by which acetaldehyde causes ethanol-evoked neuropathic 
pain are poorly understood. 
Elevated local concentrations (1-3%) of ethanol have been shown to activate the 
transient receptor potential vanilloid 1 (TRPV1) channel on primary sensory nerves to 
induce pain and neurogenic inflammation (16). A related channel, TRP ankyrin 1 
(TRPA1), is uniquely sensitive to multiple ROS, reactive nitrogen (RNS) and carbonyl 
(RCS) species (17-19). Saturated and unsaturated aldehydes, including acetaldehyde and 
4-hydroxynonenal (4-HNE), also activate TRPA1 to cause pain-like responses (20, 21). 
TRPV1, TRPA1 and other TRP channels, including the vanilloid 4 (TRPV4), are 
expressed by a subpopulation of primary sensory neurons that signal pain (19). In the 
present study, we explored the role of TRP channels in the pain-like responses evoked by 
acute and chronic ethanol ingestion in mice. 
We found that local (intraplantar) injection of ethanol in the mouse hind paw 
caused an acute nociceptive response due to direct activation of TRPV1, as previously 
reported (16). In addition, ethanol (either intraplantar or intragastric) caused a delayed 
and prolonged TRPV1-independent mechanical allodynia of the hind paw that was 
prevented by ADH and TRPA1 inhibition. Surprisingly, Schwann cells that ensheath 
plantar nerve fibers expressed ADH, which mediated the local conversion of ethanol to 
acetaldehyde. Selective deletion of TRPA1 on Schwann cells or nociceptors revealed that 
acetaldehyde, generated in the liver or locally, activates TRPA1 on Schwann cells (22) to 
produce oxidative and carbonylic stress, which target neuronal TRPA1 to sustain 
allodynia. Notably, mice fed daily with an ethanol-containing diet, which mimics chronic 
alcohol ingestion by alcoholics, developed a prolonged allodynia that was associated with 
loss of intraepidermal nerve fibers (IENF). Allodynia caused by chronic ethanol ingestion 
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was prevented by the same genetic and pharmacological disruptions of TRPA1 and 
oxidative stress that attenuated allodynia evoked by acute ethanol exposure. Thus, 
TRPA1 antagonism might represent an effective treatment for pain in alcoholics. 
 
Results 
TRPV1 mediates acute nociception but not sustained allodynia to local 
administration of ethanol 
To explore the mechanisms of alcohol-induced nociception, ethanol was 
administered locally to the hind paw of C57BL/6J mice. Injection of intraplantar ethanol 
(15-80% in 0.9% NaCl) caused dose-dependent immediate nociceptive behavior, which 
did not last more than 5 min (Figure 1A). Ethanol also produced a delayed and prolonged 
(1-6 h) mechanical allodynia (Figure 1B). The short-lived nociceptive response was 
absent in Trpv1-/- mice (Figure 1C), and in C57BL/6J mice pretreated with the TRPV1 
antagonist, SB366791 (Supplementary Figure 1A), supporting previous evidence that 
ethanol selectively targets TRPV1 to signal acute pain (16). In contrast, TRPV1 deletion 
or antagonism did not affect ethanol-evoked mechanical allodynia (Figure 1D and 
Supplemental Figure 1B). Thus, whereas direct TRPV1 engagement mediates acute 
ethanol-evoked nociception, ethanol induces sustained mechanical allodynia by a 
TRPV1-independent mechanism. Ethanol-induced nociception and allodynia were similar 
in Trpv4-/- mice and in WT littermates (Supplementary Figure 1C and D). 
 
Acetaldehyde and TRPA1 mediate sustained allodynia to local and intragastric 
administration of ethanol 
ADH mediates the first step of alcohol metabolism, converting ethanol to the 
saturated aldehyde acetaldehyde, which can activate TRPA1 (20). We examined the 
contribution of ADH and TRPA1 to ethanol-evoked allodynia. Intragastric or intraplantar 
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pretreatment of C57BL/6J mice with 4-methylpyrazole (4-Mp), a selective ADH 
inhibitor, prevented ethanol-evoked allodynia (Figure 1E and F). The nociceptive 
response evoked by intraplantar ethanol observed in Trpa1+/+ mice was also present in 
Trpa1-/- mice (Figure 1G). However, mechanical allodynia produced by intraplantar 
ethanol in Trpa1+/+ mice was absent in Trpa1-/- mice (Figure 1H). Systemic (i.p.) or 
intraplantar administration of A967079, a TRPA1 antagonist, 2 h after ethanol reversed 
sustained allodynia (Supplementary Figure 1E and F). Intraplantar injection of 
acetaldehyde (1-20 nmol) into the hind paw of C57BL/6J mice replicated the actions of 
ethanol, causing a dose-dependent immediate and transient nociceptive response (Figure 
1I), followed by a delayed and prolonged (1-8 h) allodynia (Figure 1J). Both responses 
were absent in Trpa1-/- mice (Figure 1K and L). Systemic (i.p.) or intraplantar 
administration of A967079 reversed immediate nociception and sustained allodynia 
evoked by intraplantar acetaldehyde in C57BL/6J mice (Supplementary Figure 1G-I). 
Furthermore, the acute nociceptive response and the delayed mechanical allodynia 
induced by intraplantar acetaldehyde in Trpv1+/+ mice remained unaffected in Trpv1-/- 
mice (Supplementary Figure 1J and K). The results are consistent with the hypothesis that 
ethanol induces allodynia by a mechanism that entails metabolism to acetaldehyde, which 
activates TRPA1.  
Examination of the responses evoked by local injection of ethanol or acetaldehyde 
provides mechanistic insights into alcohol-induced pain. However, the ingestion of 
alcohol causes peripheral neuropathy in alcoholics. To mimic these circumstances, we 
administered graded doses of ethanol (1-4 ml/kg of ethanol 15% in 0.9% NaCl) to mice 
by intragastric administration. Even at the highest dose (15%, 4 ml/kg, intragastric), 
ethanol did not induce acute nociception or affect motor coordination, evaluated using a 
rotarod: no falls were observed in mice receiving either vehicle (n=8) or ethanol (15%, 4 
ml/kg, n=8). However, intragastric ethanol evoked a dose-related delayed and sustained 
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(1-6 h) mechanical allodynia in C57BL/6J mice and Trpa1+/+ mice, but not in Trpa1-/- 
mice (Figure 2A and B). Ethanol-evoked mechanical allodynia was preserved in Trpv1-/- 
or Trpv4-/- mice (Supplementary Figure 1L and M). Systemic (i.p.) or intraplantar 
administration of A967079 to C57BL/6J mice reversed allodynia evoked by intragastric 
ethanol (Figure 2C and D).  
After gavage, ethanol levels in plasma, liver and paw were maximal at 30 min, and 
declined to baseline at 3 h (Figure 2E), when mechanical allodynia was maximal (e.g., 
Figure 2A). The temporal dissociation between ethanol levels in plasma and tissues and 
allodynia suggests that ethanol does not directly activate TRPA1 to cause allodynia. 
Administration of the ADH inhibitor 4-Mp (intragastric) before ethanol prevented 
allodynia (Figure 2F). These results suggest that acetaldehyde, but not ethanol, activates 
TRPA1 to initiate allodynia.  
 
Schwann cell ADH converts ethanol to acetaldehyde in peripheral tissues 
Ethanol is mainly converted to acetaldehyde by ADH in the liver. However, ADH 
is expressed in other tissues (23-26). We detected mRNAs encoding ADH1, ADH5 and 
ADH7 in homogenates of mouse paw (Figure 3A). ADH immunoreactivity was confined 
to the nerve trunk within the paw, where it was co-expressed with S100, a specific marker 
of Schwann cells, but not in PGP9.5-positive nerve fibers (Figure 3B and C and 
Supplementary Figure 2A). Exposure of cultured mouse Schwann cells to ethanol 
induced the generation of acetaldehyde, a response that was prevented by 4-Mp (Figure 
3D). Local (intraplantar) administration of ethanol to the paw also resulted in increased 
paw tissue levels of acetaldehyde within 15 min (Figure 3E). The local (intraplantar) 
administration of 4-Mp inhibited acetaldehyde formation (Figure 3F) and allodynia 
(Figure 1F) induced by intraplantar ethanol. The effects of intragastric ethanol on 
allodynia and acetaldehyde levels were partially reduced by pretreatment with 
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intraplantar (Figure 3G and H), or completely attenuated by, intragastric 4-Mp (Figure 
3H and 2F). These results suggest that Schwann cells in the paw express ADH and 
convert ethanol to acetaldehyde. This local generation to acetaldehyde, together with the 
hepatic generation of acetaldehyde, can cause TRPA1-dependent sustained allodynia. 
 
Acetaldehyde via TRPA1 generates ROS that sustain ethanol-evoked allodynia 
To strengthen the hypothesis that acetaldehyde initiates allodynia by activating 
TRPA1, we treated mice with systemic (0.1-1 mg/kg, i.p.) acetaldehyde. Acetaldehyde 
(i.p.) did not affect motor coordination, as no falls was observed with either vehicle (n=8) 
or acetaldehyde (1 mg/kg, n=8). Acetaldehyde (i.p.) did not cause detectable acute 
nociceptive behavior, but evoked a dose-dependent, delayed and prolonged (1-8 h) 
mechanical allodynia in C57BL/6J mice (Figure 4A). Acetaldehyde did not cause 
allodynia in Trpa1-/- mice (Figure 4B). Systemic (i.p.) and intraplantar A967079 
prevented acetaldehyde-evoked allodynia in C57BL/6J mice (Figure 4C and D). 
However, acetaldehyde formation in liver and paw after intragastric ethanol did not 
coincide with allodynia (Figure 4E); the levels of acetaldehyde in the liver and paw had 
returned to baseline by 3 h after intragastric ethanol (Figure 4E), when allodynia was 
robustly maintained (Figure 2A). Furthermore, administration of the ADH inhibitor 4-Mp 
(intragastric) after ethanol did not affect allodynia (Figure 4F). These results suggest the 
existence of additional mechanisms of ethanol-induced allodynia.  
Both ethanol and acetaldehyde can release ROS (27-29). ROS and their carbonylic 
byproducts, including 4-HNE, activate TRPA1 (17, 21). To examine the contribution of 
ROS to ethanol-evoked allodynia, we treated mice with the ROS scavenger, phenyl-α-
tert-butyl nitrone (PBN). PBN (i.p. or intraplantar) reversed the allodynia evoked by 
ethanol (both intraplantar and intragastric) (Figure 4G and H; Supplementary Figure 3A 
and B) or acetaldehyde (Figure 4I and J; Supplementary Figure 3C and D). Ethanol 
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(intragastric or intraplantar) increased H2O2 and 4-HNE levels in the paw (Figure 5A and 
B). However, while H2O2 levels were elevated for 3 h, 4-HNE content, measured by 
either immunofluorescence or by a biochemical assay, persisted for 6 h (Figure 5A and 
B). To test the hypothesis that the late phase of allodynia was mainly due to RCS, N-
acetyl cysteine (NAC), which efficiently scavenges α,β-unsaturated aldehydes, including 
4-HNE (30), was given (i.p.) to mice 5 h after ethanol (intragastric). NAC (i.p.) 
attenuated mechanical allodynia at 6 h (Figure 5C). These results suggest that carbonylic 
derivatives, which are more stable and longer acting than ROS (30), sustain the final 
phase of allodynia. To support this hypothesis, PBN, which selectively scavenges ROS, 
was ineffective in the final phase of allodynia (Figure 5C).  
Administration of the ADH inhibitor 4-Mp (Figure 5D) or the ROS scavenger, PBN 
(Figure 5E), blunted the ethanol-induced increase in H2O2 levels. Acetaldehyde (i.p. or 
intraplantar) increased H2O2 in paw tissue (Figure 5F), an effect that was inhibited by 
PBN (Figure 5G). Surprisingly, we observed that pharmacological blockade or genetic 
deletion of TRPA1 attenuated both ethanol- and acetaldehyde-evoked increases in H2O2 
in the paw (Figure 5E and 5G-I). We have recently reported the presence of different 
NOX isoforms in Schwann cells of the mouse sciatic nerve, where they co-localize with 
TRPA1 to increase oxidative stress (22). Here, we observed that Schwann cells of plantar 
nerve fibers expressed NOX1 and TRPA1 (Figure 6A and B and Supplementary Figure 
2A). A NOX1 antagonist (ML171, i.p.) reversed allodynia evoked by ethanol 
(intragastric) and acetaldehyde (i.p.) (Figure 6C).  
Our results suggest that ADH in the liver or in Schwann cells of the sciatic nerve 
converts ethanol to acetaldehyde; Schwann cell-derived acetaldehyde might activate 
TRPA1 in an autocrine manner to generate ROS and RCS, which could amplify and 
sustain allodynia. To specifically define the role of Schwann cell TRPA1 in ethanol-
evoked nociception, we studied mice with Schwann cell-specific deletion of TRPA1. 
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Mice with conditional ablation of TRPA1 in Schwann cells (Plp1-CreERT;Trpa1fl/fl) (22) 
exhibited a normal acute nociception after intraplantar ethanol or AITC (TRPA1 agonist) 
(Supplementary Figure 4A). As these two responses are mediated by neuronal TRPV1 
and TRPA1, respectively, the results indicate that the neuronal channel is unaffected by 
deletion of Schwann cell TRPA1. However, allodynia and generation of H2O2 in the paw 
evoked by intraplantar or intragastric ethanol were attenuated in Plp1-CreERT;Trpa1fl/fl 
mice (Figure 6D and E).  
To further support the involvement of Schwann cell TRPA1 in ethanol-evoked 
mechanical allodynia, mice were locally treated with the TRPA1 antisense 
oligonucleotide (TRPA1 AS-ODN) or its mismatched (TRPA1 MM-ODN) analogue 
(both intraplantar) (Supplementary Figure 4C) or with the activated form of tamoxifen (4-
hydroxytamoxifen, 4-OHT) (intraplantar) (Supplementary Figure 4G). Both treatments 
were given by injection in the vicinity of the plantar nerve trunk, before ethanol 
(intraplantar or intragastric). In mice treated with TRPA1 AS-ODN or 4-OHT, acute 
nociception responses by intraplantar ethanol or AITC (dependent on neuronal TRPV1 
and TRPA1, respectively) were preserved (Supplementary Figure 4E and I), indicating 
that neuronal TRPV1 and TRPA1 were unaffected. However, colocalization of TRPA1 
with the Schwann cell marker, S-100, in the plantar nerve was markedly reduced 
(Supplementary Figure 4D and H), confirming selective deletion of TRPA1 in Schwann 
cells. After intragastric ethanol, mechanical allodynia was attenuated solely in the paw 
treated with the TRPA1 AS-ODN, while it was unaffected in the TRPA1 MM-ODN 
treated paw (Supplementary Figure 4F). Similar results were obtained with local 
treatment with 4-OHT. Notably, 4-OHT attenuated mechanical allodynia evoked by 
intragastric ethanol only on the paw treated with 4-OHT, but not in the contralateral paw 
(Supplementary Figure 4J). These data support the hypothesis that ethanol-evoked 
allodynia is initiated and maintained by Schwann cell TRPA1.  
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To specifically investigate the contribution of neuronal TRPA1, we studied mice 
with selective deletion of TRPA1 in primary sensory neurons (Adv-Cre;Trpa1fl/fl) (31). 
AITC-induced nociception was attenuated in Adv-Cre;Trpa1fl/fl mice, which confirms 
deletion of the functional channel (Supplementary Figure 4B). In Adv-Cre;Trpa1fl/fl mice, 
ethanol-induced acute nociception was preserved (Supplementary Figure 4B). However, 
whereas allodynia evoked by intragastric or intraplantar ethanol was attenuated, H2O2 
formation was unaffected (Figure 6F and G). Thus, in contrast with the Schwann cell 
channel, TRPA1 expressed by nociceptor signals pain, but does not contribute to 
oxidative stress generation. 
 
Chronic ethanol ingestion evokes ROS formation and allodynia dependent on 
Schwann cell TRPA1 
In WT mice, daily ingestion of an ethanol (5% for 28 d) containing diet (32) 
induced a progressively increasing mechanical allodynia that was apparent at 5-8 d, 
stabilized after two wk and maintained for the entire period of observation (Figure 7A 
and B). Both Trpa1-/- and Plp1-CreERT;Trpa1fl/fl mice were protected from the 
development of allodynia (Figure 7B). At day 28 after the initiation of the ethanol diet, 
the allodynia observed in WT mice was reversed by treatment (i.p.) with the TRPA1 
antagonist, A967079, or with the ROS scavenger, PBN (Figure 7C). At day 28, WT mice 
showed increased levels of H2O2 and 4-HNE in the plantar nerve that were attenuated in 
Trpa1-/- and Plp1-CreERT;Trpa1fl/fl mice (Figure 7D). However, the loss of PGP9.5 
positive IENF observed at day 28 was unaffected in either Trpa1-/- or Plp1-
CreERT;Trpa1fl/fl mice (Figure 7E). At day 28, the levels of ethanol or ACD in the paw of 
Trpa1-/- and Plp1-CreERT;Trpa1fl/fl mice were not different from those measured in 
respective WT and control mice (Supplementary Figure 5A-D). 
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Ethanol evokes ADH- and TRPA1-dependent ROS formation by human Schwann 
cells 
Our findings reveal an unexpected but critical role for Schwann cells in ethanol-
evoked mechanical allodynia in mice. To assess whether these findings could translate to 
humans, we studied primary cultures of human Schwann cells (HSC) and Schwann cells 
in sections of human skin. HSC in culture expressed immunoreactive S100 and 
immunoreactive ADH (Figure 8A). In nerve bundles in biopsies of human skin, 
immunoreactive ADH colocalized with S100 (Figure 8B and Supplementary Figure 2B). 
mRNA encoding multiple isoforms of ADH (1A, 1B, 1C and 5) was amplified from HSC 
in culture (Figure 8C). Exposure of HSC to ethanol caused a concentration-dependent 
generation of acetaldehyde that was inhibited by 4-Mp, and thus depends on ADH 
activity (Figure 8D). S100-positive HSC in culture (Figure 8E) and in sections of human 
skin also expressed immunoreactive TRPA1 (Figure 8F and Supplementary Figure 2B). 
Cultured HSC expressed TRPA1 mRNA (Figure 8G). Exposure of HSC to AITC, 
acetaldehyde or H2O2 elicited increases in intracellular calcium that were attenuated by 
A967079 (Figure 8H). Prolonged exposure of HSC to ethanol induced a delayed and 
sustained increase in calcium responses, which was attenuated by pretreatment with 4-Mp 
or A967079 (Figure 8I). S100-positive HSC in culture and in sections of human skin also 
expressed immunoreactive NOX1 (Figure 8J and K and Supplementary Figure 2B). In 
addition, cultured HSC expressed NOX1 mRNA (Figure 8L). AITC, acetaldehyde or 
H2O2 elicited calcium
 dependent increases in H2O2 in HSC that were reduced by 
A967079 (Figure 8M). 
 
Discussion 
Our results show that intraplantar injection of ethanol in the mouse hind paw causes 
two sensory responses, which are temporally and mechanistically distinct. After an 
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immediate and short-lived (5 min) nociceptive response, mice exhibited a delayed and 
prolonged (1-6 h) mechanical allodynia. TRPV1 antagonism or deletion prevented the 
immediate nociceptive response, which is thus mediated by ethanol activation of TRPV1, 
as previously reported (16). In contrast, TRPV1 disruption did not affect the delayed and 
sustained mechanical allodynia, which occurs by a different mechanism. 
Genetic or pharmacological impairment of ADH that results in increased 
acetaldehyde levels enhances the susceptibility of affected individuals to alcohol-evoked 
symptoms (13, 14). Our observation that pretreatment with the ADH inhibitor, 4-Mp, 
prevented the allodynia evoked by intraplantar ethanol and that intraplantar injection of 
acetaldehyde caused allodynia similar to that evoked by ethanol support the hypothesis 
that acetaldehyde mediates the prolonged allodynic effect of ethanol. The findings that 
genetic deletion or pharmacological antagonism of TRPA1 prevented ethanol- and 
acetaldehyde-evoked allodynia are consistent with the hypothesis that the aldehyde and 
not its precursor gates TRPA1 (20) and plays a major role in the allodynia that mimics 
the neuropathic pain observed in alcoholics. In contrast, deletion of TRPV4, a proalgesic 
channel expressed by a subset of nociceptors, did not affect either acute nociception or 
allodynia. Thus, while acute nociception is due to a direct action of ethanol on TRPV1, 
delayed and sustained allodynia is mediated by TRPA1, via ADH-dependent generation 
of acetaldehyde.  
We investigated the contribution of TRPA1 to pain after oral administration of 
ethanol, which more closely resembles the situation in alcoholics. In contrast to 
intraplantar administration, intragastric administration of ethanol did not cause acute 
pain-related behavior. However, intragastric ethanol did cause delayed and sustained 
allodynia in wild-type but not Trpa1-/- mice; deletion of either TRPV1 or TRPV4 did not 
affect allodynia. The ability of intraperitoneal acetaldehyde to mimic the response evoked 
by intragastric ethanol implicates this metabolite as a mediator of TRPA1-dependent 
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allodynia. Although the major site of alcohol metabolism is the liver, where the bulk of 
acetaldehyde is generated (25, 26), several extrahepatic cells express ADH (23, 24). The 
ADH inhibitor, 4-Mp, when given locally (intraplantar administration), prevented 
acetaldehyde increase and allodynia evoked by local (intraplantar) ethanol, and, although 
partially, reduced increases in acetaldehyde and allodynia elicited by intragastric ethanol. 
Complete inhibition of allodynia and increases in acetaldehyde levels evoked by 
intragastric ethanol were, however, obtained by systemic 4-Mp administration. These 
results suggest that acetaldehyde, which mediates allodynia, derives in part from the 
systemic circulation, and in part from local production within the paw tissue. ADH 
mRNA and protein were confined to Schwann cells that ensheath sensory nerve fibers in 
the paw. The ability of the paw tissue and cultured mouse Schwann cells to convert 
ethanol into acetaldehyde in a 4-Mp-sensitive manner supports the proposal that Schwann 
cells are the local source of acetaldehyde, which engages TRPA1 to mediate allodynia. 
Whereas the TRPA1 antagonist, A967079, inhibited ethanol-evoked allodynia 
when administered before or after ethanol, the ADH inhibitor, 4-Mp, prevented allodynia 
only when given before ethanol. This finding suggests that, whereas TRPA1 engagement 
is constantly required, acetaldehyde is necessary to initiate, but is not sufficient to 
maintain, allodynia. The transient (1-h duration) increase in acetaldehyde levels in the 
paw, compared to the sustained allodynia (6 h), strengthens the view that the prolonged 
allodynia is not maintained by acetaldehyde. Acetaldehyde can generate ROS (27, 29), 
which are among the several endogenous ligands of TRPA1 (17-19). H2O2 levels peaked 
in paw homogenates 1-3 h and returned to baseline 6 h after ethanol. However, in the 
mouse paw immunostaining for the carbonylic byproduct of oxidative stress, 4-HNE (33), 
a known TRPA1 activator (21), increased 3 h, and peaked 6 h after ethanol when 
allodynia was still robustly present. In agreement with the time courses of H2O2 and 4-
HNE levels in the mouse paw, treatment with the ROS scavenger, PBN, attenuated 
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allodynia 3 h, but not 6 h, after ethanol, while the aldehyde scavenger, NAC, was 
effective 6 h after ethanol. These findings suggest that TRPA1 engagement by mediators 
efficiently scavenged by PBN does not outlast 4 h after exposure to ethanol, whereas 
attenuation of allodynia 6 h after ethanol is provided exclusively by compounds able to 
scavenge aldehydic compounds, such as 4-HNE. The ability of the ROS scavenger, PBN, 
to attenuate paw allodynia indicates that oxidative stress sustains allodynia and raises the 
question of how ethanol/acetaldehyde generate ROS. We recently reported in a mouse 
model of sciatic nerve injury that ROS, which sustain mechanical allodynia, are produced 
via the TRPA1/NOX1 pathway in Schwann cells ensheathing sciatic nerve fibers (22). 
Therefore, we investigated the possibility that a similar mechanism contributes to 
ethanol-evoked allodynia. In support of this hypothesis, Plp1-CreERT;Trpa1fl/fl mice, 
which selectively lack TRPA1 in Schwann cells, showed attenuated allodynia and 
reduced H2O2 levels in paw tissue. NOX1 has been reported as the major enzyme isoform 
responsible for the TRPA1-dependent oxidative burst in Schwann cells (22). We 
confirmed this finding since the selective NOX1 inhibitor, ML171 (34), attenuated 
ethanol-evoked allodynia. 
Finally, we asked whether the TRPA1 which mediates ethanol-evoked allodynia is 
exclusively the channel expressed by Schwann cells, or if the neuronal channel might 
also contribute. Mice with selective deletion of TRPA1 in primary sensory neurons, Adv-
Cre;Trpa1fl/fl mice (31), exhibited a markedly attenuated  ethanol-evoked paw allodynia. 
However, the increased levels of H2O2 in the paw tissue were unaffected. These 
observations indicate that the Schwann cell TRPA1/NOX1 pathway is necessary to 
maintain the prolonged oxidative stress generation required to target the neuronal 
TRPA1, which eventually sustains allodynia. Plp1-CreERT;Trpa1fl/fl mice are selectively 
deficient of TRPA1 in the Schwann cell and oligodendrocyte lineage. Thus, the 
implication of oligodendrocytes in the brain signaling of allodynia evoked by intragastric 
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ethanol should be considered. However, several observations suggest that initiation and 
maintenance of paw allodynia is promoted by a series of local events driven by TRPA1 of 
Schwann cell ensheathing plantar nerve. Plp1-CreERT;Trpa1fl/fl mice not only failed to 
produce allodynia, but were unable to generate the local oxidative stress response that is 
required to sustain allodynia. Local treatment with a TRPA1 AS-ODN or with the active 
tamoxifen metabolite, 4-OHT, which directly binds to the tamoxifen-inducible estrogen 
receptor, attenuated intragastric ethanol-evoked allodynia only in the treated paw, without 
affecting the pain response in the contralateral side. These findings imply that the drugs 
did not diffuse to distant sites, including the brain, but maintained their action confined to 
the treated paw. Thus, the most parsimonious hypothesis is that Schwann cell TRPA1, by 
promoting local oxidative stress generation, is necessary and sufficient to sustain ethanol-
evoked allodynia. Nonetheless, these observations do not exclude a contribution of 
oligodendrocyte TRPA1 to the central processing of the pain response. The generation of 
mice lacking TRPA1 solely in Schwann cells would be required to definitively determine 
the selective role of TRPA1 in this cell type. 
Painful neuropathy is produced by chronic alcohol ingestion and is associated with 
peculiar pathological features, such as the loss of IENF (5). We reproduced a chronic 
condition in mice by feeding them an ethanol containing diet. The observation that both 
Trpa1-/- and Plp1-CreERT;Trpa1fl/fl mice did not develop allodynia indicated that TRPA1 
and specifically the channel expressed by Schwann cells is necessary and sufficient to 
generate the painful condition. Reduced levels of either H2O2 or 4-HNE in the plantar 
nerve of Trpa1-/- and Plp1-CreERT;Trpa1fl/fl mice and the ability of the TRPA1 antagonist 
and the ROS scavenger to reverse allodynia, suggest that chronic ethanol ingestion 
activates a proalgesic mechanism identical to that induced by acute ethanol exposure. 
Thus, the oxidative stress that signals pain is generated by a sustained gating of Schwann 
cell TRPA1 by acetaldehyde generated by the daily ethanol ingestion. 
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Our results show that in mice receiving chronic ethanol administration deletion of 
Schwann cell TRPA1 does not ameliorate IENF loss, but does attenuate allodynia. Thus, 
Schwann cell TRPA1 and the ensuing oxidative stress burst are not crucial for the 
neuropathy and there is no stringent correspondence between IENF degeneration and 
neuropathic pain. After the loss of IENF, the remaining extraepithelial nerve fibers with 
their ensheathing Schwann cells are sufficient to elicit mechanical allodynia. Various 
interventions, including the immunomodulator, minocycline (35), erythropoietin (36), a 
poly(ADP-ribose) polymerase inhibitor (37) and a TRPA1 antagonist (38), have been 
reported to attenuate IENF loss and the ensuing neuropathic pain-responses. A series of 
differences may explain the discrepancy with our current data, including the causative 
agent of the neuropathy, alcohol vs. streptozotocin and paclitaxel, or in the case of 
TRPA1, systemic treatment with an antagonist that non-selectively targets TRPA1, not 
solely in Schwann cells, but in all cells where it is expressed.  
The presence of thiamine deficiency in heavy alcohol drinkers suggested that the 
beriberi neuropathy was the underlying cause of the neurological symptoms in alcoholics. 
However, investigation of respective clinicopathological features has clearly 
differentiated the two conditions (7). Alcoholic neuropathy is sensory-dominant and 
predominantly shows loss of small fibers, while thiamine deficiency neuropathy is motor-
dominant with mainly large fiber loss (7). The small-fiber polyneuropathy documented in 
heavy alcohol drinkers with normal thiamine status (39) further supported the direct role 
of alcohol and acetaldehyde, and not of thiamine deficiency, in alcoholic neuropathy (7, 
39, 40). Assessment of ethanol-evoked allodynia in mice underscores the implication of 
TRPA1 either in acute (single administration) or chronic (prolonged exposure) settings. 
However, pain (with or without burning quality) is the initial major symptom of alcoholic 
neuropathy; it develops slowly, extending over a period of months, and is associated with 
allodynia and hyperalgesia (3). Thus, a limitation of the present murine study is that only 
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one (mechanical allodynia) among the various pain modalities reported by alcoholics has 
been investigated.  
While TRPV1 is key to evoke the acute nociceptive behavior caused by local 
exposure to ethanol, TRPA1 uniquely mediates the prolonged paw allodynia that models 
in mice one pain symptom observed in patients. However, multiple ethanol-derived 
mediators contribute to the TRPA1-mediated paw allodynia. Acetaldehyde generated by 
liver ADH (Supplementary Figure 6) and locally by Schwann cell ADH commits 
Schwann cell TRPA1/NOX1 to generate ROS. ROS released from Schwann cells engage 
TRPA1 in nociceptors initially and up to 3 h after ethanol. The peroxidation-dependent 
generation of carbonylic byproducts, including 4-HNE, sustains the final TRPA1 
targeting. The translational value of the present findings is strengthened by the 
observation that human Schwann cells are fully equipped to exert all the functions found 
in mouse Schwann cells. Human Schwann cells express ADH, TRPA1 and NOX1 
mRNA and protein, and are capable of converting ethanol into acetaldehyde. Human 
Schwann cells respond to ethanol (via acetaldehyde), acetaldehyde and H2O2 with a 
TRPA1-dependent calcium response and the ensuing generation of oxidative stress. Thus, 
inhibition of any of the steps reported here in mice may be translated to human Schwann 
cells and could be beneficial to attenuate pain associated with alcohol consumption in 
patients. 
The presence of ADH in Schwann cells that express TRPA1/NOX1 and their ability 
of generating oxidative stress identifies an autocrine pathway that we propose as a major 
contributing mechanism in alcohol-induced mechanical allodynia. Moreover, this 
pathway may be important in other conditions produced by exposure to alcohol. The 
reported presence of TRPA1 in oligodendrocytes (41) suggests that similar detrimental 
mechanisms may operate in the central nervous system to mediate the toxic effect 
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associated with alcohol ingestion. Further studies are required to explore whether 




The following mouse strains were used: C57BL/6J (male, 20-25 g, 5-6 wk; 
Envigo); littermate WT (Trpa1+/+) and TRPA1-deficient mice (Trpa1-/-, B6.129P-
Trpa1tm1Kykw/J, 25-30 g, 5-8 wk, Jackson Laboratories) (42); littermate WT (Trpv4+/+) 
and TRPV4-deficient (Trpv4-/-) mice (25-30 g, 5-8 wk) (43); and littermate WT 
(Trpv1+/+) and TRPV1-deficient mice (Trpv1-/-, B6.129X1-Trpv1tm1Jul/J, 25-30 g, 5-8 wk, 
Jackson Laboratories). All these strains were generated by C57BL/6 background. 
To selectively delete Trpa1 gene in primary sensory neurons, 129S-Trpa1tm2Kykw/J 
mice (floxed Trpa1, Trpa1fl/fl, Stock No: 008649; Jackson Laboratories), which possess 
loxP sites on either side of the S5/S6 transmembrane domains of the Trpa1 gene, were 
crossed with hemizygous Advillin-Cre male mice (44). The progeny (Adv-Cre;Trpa1fl/fl) 
was genotyped by standard PCR for Trpa1 and Advillin-Cre. Mice negative for Advillin-
Cre (Adv-Cre-;Trpa1fl/fl) were used as control. Successful Advillin-Cre driven deletion of 
TRPA1 mRNA was confirmed by RT-qPCR (45). To generate mice in which the Trpa1 
gene was conditionally silenced in Schwann cells/oligodendrocytes homozygous 129S-
Trpa1tm2Kykw/J (floxed TRPA1, Trpa1fl/fl, Stock No: 008649, Jackson Laboratories), were 
crossed with hemizygous B6.Cg-Tg(Plp1-CreERT)3Pop/J mice (Plp1-CreERT, Stock No: 
005975, Jackson Laboratories), expressing a tamoxifen-inducible Cre in myelinating cells 
(Plp1, proteolipid protein myelin 1) (22). The progeny (Plp1-Cre;Trpa1fl/fl) was 
genotyped by standard PCR for Trpa1 and Plp1-CreERT (22). Mice negative for Plp1-
CreERT (Plp1-Cre-;Trpa1fl/fl) were used as control. Both positive and negative mice to 
CreERT and homozygous for floxed Trpa1 (Plp1-CreERT;Trpa1fl/fl and Plp1-CreERT-
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;Trpa1fl/fl, respectively) were treated with intraperitoneal (i.p.) tamoxifen (1 mg/100 µl in 
corn oil, once a day, for 5 consecutive d) (22), resulting in Cre-mediated ablation of 
Trpa1 in PLP-expressing Schwann cells/oligodendrocytes. Successful Cre-driven 
deletion of TRPA1 mRNA was confirmed by RT-qPCR (22). In addition, some Plp1-
CreERT;Trpa1fl/fl and Plp1-CreERT-;Trpa1fl/fl were treated with the activated form of 
tamoxifen (4-hydroxytamoxifen, 4-OHT, intraplantar, i.pl., 0.02 mg/10 µl once a day for 
4 consecutive d). 
 
Study design  
Group size of n=8 animals for behavioral experiments were determined by sample 
size estimation using G*Power (v3.1) (46)  to detect size effect in a post-hoc test with 
type 1 and 2 error rates of 5 and 20%, respectively. Allocation concealment of mice to 
vehicle(s) or treatment(s) group was performed using a randomization procedure 
(http://www.randomizer.org/). The assessors were blinded to the identity (genetic 
background or allocation to treatment group) of the animals. Identity of the animals was 
unmasked to assessors only after data collection. Every effort has been made to minimize 
the discomfort and pain of the animals in each phase of the study. Mice were housed in a 
temperature- and humidity-controlled vivarium (12 h dark/light cycle, free access to food 
and water, 8 animals per cage). Mice were acclimatized in a quiet, temperature-controlled 
room (20-22°C) for 1 h before behavioral studies, that were done between 9 a.m. and 5 
p.m. Animals were anaesthetized with a mixture of ketamine and xylazine (90 mg/kg and 
3 mg/kg, respectively, i.p.) and euthanized with inhaled CO2 plus 10-50% O2. If not 
otherwise indicated, reagents were obtained from Sigma-Aldrich (Milan, Italy). 
In functional and biochemical studies ethanol was given by i.pl. (30%) or i.g. (15%, 
4 ml/kg) administration and acetaldehyde by i.pl. (20 nmol) or i.p. (0.1 mg/kg) 
administration. Vehicle of i.pl. or i.g. ethanol and i.pl. or  i.p. acetaldehyde  was 0.9% 
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NaCl. Vehicle the various drugs was 4% DMSO and 4% Tween80 in 0.9% NaCl for i.pl. 
or i.p. administration and, 0.5% carboxymethylcellulose for i.g. administration. Twenty 
µl/site were injected in all i.pl. administrations. SB366791, N-(3-methoxyphenyl)-4-
chlorocinnamide (1 mg/kg, i.p.) or vehicle were administered 30 min before i.pl. ethanol 
or vehicle. A967079, [(1E,3E)-1-(4-Fluorophenyl)-2-methyl-1-penten-3-one oxime] and 
phenyl-α-tert-butyl nitrone (PBN) (both, 100 mg/kg, i.p. or 100 µg i.pl.) or their vehicle, 
were administered 1 h after i.pl. or i.g. ethanol and i.pl. or i.p. acetaldehyde or their 
vehicle. PBN (100 mg/kg, i.p.) or vehicle were also given 5 h after i.g. ethanol. 4-
methylpyrazole (4-Mp, 50 mg/kg, i.g. or 100 µg, i.pl.) or vehicle were administered 30 
min before i.pl. or i.g. ethanol or vehicle and 2 h after i.g. ethanol or vehicle. N-acetyl 
cysteine (NAC, 250 mg/kg, i.p.) or vehicle were administered 5 h after i.g. ethanol. 
ML171 [2-acetylphenothiazine] (60 mg/kg, i.p.) (Tocris Bioscience) or vehicle were 
administered 2 h after i.g. ethanol and i.p. acetaldehyde or their vehicles.  
Phosphorothioate-modified TRPA1 AS-ODN (sequence: 5’-
TATCGCTCCACATTGCTAC-3’) and TRPA1 MM-ODN (sequence: 5’-
ATTCGCCTCACATTGTCAC-3’) (22) (10 nmol/10 µl, i.pl.) were administered once a 
day for 4 consecutive d. Some mice treated with TRPA1 AS/MM-ODN or with 4-OHT 
were tested for the acute nociceptive response to AITC (20 nmol, i.pl.) or ethanol (30%, 
i.pl.) or their vehicles (0.5% DMSO or 0.9% NaCl, respectively).  
Blood for ethanol assay was obtained from anesthetized mice at 15, 30, 60 and 180 
min after i.g. ethanol. Liver and hind paw tissues for ethanol and acetaldehyde assays 
were obtained from mice euthanized 15, 30, 60 and 180 min after i.pl. or i.g. ethanol. 
Some mice were treated with 4-Mp (100 µg, i.pl. or 50 mg/kg, i.g.) 30 min before or 1 hr 
after i.pl. or i.g. ethanol or their vehicles and euthanized 2 h after ethanol. For H2O2 
assay, hind paw tissues were taken from mice euthanized before and 1, 3, 6 and 8 h after 
i.pl. or i.g. ethanol and acetaldehyde or their vehicles. In additional experiments, paw 
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tissues were taken from mice treated 3 h before with i.pl. or i.g. ethanol or acetaldehyde 
or their vehicles that 1 h before with A967079 (100 mg/kg, i.p.) or PBN (100 mg/kg, i.p.) 
or their vehicles. For the 4-HNE-histidine protein adducts assay, paw tissues were taken 
from mice euthanized before and 1, 3, 6 and 8 h after i.g. ethanol. 
For chronic alcohol administration, one or two mice were housed per cage and were 
initially fed the control Lieber-DeCarli diet (F1259, Bio-Serv) ad libitum for 5 d to 
acclimatize them to the liquid food and tube feeding. Afterward, ethanol-fed groups were 
allowed free access to the ethanol Lieber-DeCarli diet containing 5% (vol/vol) ethanol 
(F1258, Bio-Serv), daily for 28 d (32). Control mice were pair-fed (i.e. calorically 
matched to the ethanol-fed mice) with the control diet in which equal calories of maltose-
dextrin was consumed in place of ethanol (32). The feeding tubes contained 30 or 50 ml 
of ethanol or control liquid diet for one or two mice, respectively. Mice in both the 
experimental groups were healthy and, displayed normal reflexes and alertness. A967079 
and PBN (both, 100 mg/kg, i.p.), were administered at day 28 after ethanol or control 
liquid diet. Liver and paw tissues for ethanol and acetaldehyde assays were obtained from 
mice euthanized at day 28 after ethanol or control liquid diet. 
 
Acute nociceptive behavior, hind paw mechanical allodynia and rotarod test 
To assess acute nociceptive responses, mice were placed in a plexiglass chamber 
immediately after ethanol (15-80% in 0.9% NaCl, i.pl.), acetaldehyde (0.1-10 nmol/site in 
NaCl, i.pl.), allyl isothiocyanate (AITC, 10 nmol in 0.5% DMSO, i.pl.) or their respective 
vehicles, and the total time (nociception time, s) spent in licking and lifting the injected 
right hind limb (21) was recorded for 5 min. Mechanical allodynia was evaluated by 
applying the von Frey filaments to the posterior hind paw of mice, before (basal 
threshold) and after (1-24 h) ethanol (15-80% in 0.9% NaCl, i.pl.; 1-4 ml/kg of 15% in 
0.9% NaCl, i.g.), acetaldehyde (1-20 nmol/site in 0.9% NaCl, i.pl.; 0.1-1 mg/kg in 0.9% 
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NaCl, i.p.) or respective vehicles and, in mice fed with the Lieber-DeCarli or control diet 
over 28 d. Mechanical threshold was determined by using the up-and-down paradigm 
(47).  
Locomotor function, coordination, and sedation of animals were tested by using a 
rotarod apparatus (UgoBasile). Twenty-four h before the experiments, mice were trained 
on the rotarod apparatus, programmed at 8 rpm, until they remained without falling for 60 
s. The day of the experiment, the latency (s) to the first fall and the number of falls were 
recorded. Cut-off time was 240 s.  
 
Ethanol, acetaldehyde, H2O2 and 4-HNE-histidine protein adducts assays 
For ethanol assay, blood taken into heparin containing syringes via direct cardiac 
puncture from anesthetized mice, was centrifuged at 10,000 rpm for 5 min and the plasma 
was collected. For ethanol and acetaldehyde assay paw and liver tissues from euthanized 
mice were homogenized in PBS (0.1 M) by using a tissue homogenizer (Qiagen SpA) for 
30 s, centrifuged 10,000 rpm for 10 min, and supernatants collected. Ethanol content was 
determined by a colorimetric assay (ab65343, Abcam) according to the manufacturer’s 
protocol, and expressed as nmol/ml (plasma) and nmol/mg of protein (tissues). 
Acetaldehyde content (nmol/mg of protein) was determined by a colorimetric assay 
(Megazyme) according to the manufacturer’s protocol.  
The H2O2 content was determined in the paw tissue by using the Amplex Red
® 
assay (Invitrogen). Briefly, tissues were rapidly placed into modified Krebs/HEPES 
buffer (composition in mmol/l: 99.01 NaCl, 4.69 KCl, 2.50 CaCl2, 1.20 MgSO4, 1.03 
KH2PO4, 25.0 NaHCO3, 20.0 Na-HEPES, and 5.6 glucose [pH 7.4]), minced and 
incubated with Amplex red (100 µM) and HRP (1 U/ml) (1 hour, 37°C) in modified 
Krebs/HEPES buffer protected from light (48). Fluorescence excitation and emission 
were at 540 and 590 nm, respectively. H2O2 production was calculated using H2O2 
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standard and expressed as µmol/l of mg of dry tissue. 
4-HNE-histidine (4-HNE-His) protein adduct content was quantified in paw tissues 
by a colorimetric assay (OxiSelect HNE-His Adduct ELISA Kit, Cell Biolabs, Inc) 
according to manufacturer’s protocol. Paw tissues were homogenized in PBS (0.1 M), 
added of a protease inhibitor cocktail (1 tablet/100 ml) for 30 s and centrifuged (10,000 
rpm, 10 min, 4°C). Supernatants were assayed for the measurement of total protein 




Human embryonic kidney 293 (HEK293) cells stably transfected with the cDNA 
for human TRPA1 (hTRPA1-HEK293) were cultured as previously described (49). 
Human Schwann cells (HSC, #1700, CliniScience) were cultured in Schwann cell 
medium (#1701, CliniScience) according to the manufacturer’s protocol. Human alveolar 
type II epithelium-like adherent cell line (A549) (CCL-185™, American Type Culture 
Collection) were cultured in RPMI with 10% FBS, 2 mM glutamine, 100 U penicillin, 
100 µg/ml streptomycin and 1 mM HEPES. All cells were used when received without 
further authentication.  
Schwann cells were isolated from sciatic nerves of C57BL/6J mice. The epineurium 
was removed, and nerve explants were divided into 1 mm segments and dissociated 
enzymatically using collagenase (0.05%) and hyaluronidase (0.1%) in HBSS (2 h, 37°C). 
Cells were collected by centrifugation (800 rpm, 10 min, room temperature) and the 
pellet was resuspended and cultured in DMEM containing: 10% fetal calf serum, 2 mM 
L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin. Three days later, cytosine 
arabinoside (10 mM) was added to remove fibroblasts. All cells were cultured in an 
atmosphere of 95% air and 5% CO2 at 37°C. 
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Assays in cultured cells 
Calcium imaging. HSC were plated on glass coated (poly-L-lysine, 8.3 µM) 
coverslips and [Ca2+]i response was measured as previously reported (22). HSC were 
exposed to AITC (100 µM), H2O2 (10 mM) and acetaldehyde (10 mM) or their vehicles 
(0.1% DMSO or 0.9% NaCl) in the presence or absence of A967079 (50 µM) or its 
vehicle (0.3% DMSO). In other experiments, HSC were exposed to ethanol (10 mM) or 
its vehicle. In this case the delayed [Ca2+]i response was monitored for ~150 min in the 
presence or absence of A967079 (50 µM) or 4-Mp (100 µM) or their vehicle (0.3% 
DMSO). Results were expressed as % increase in Ratio340/380 over baseline normalized to 
the maximum effect induced by ionomycin (5 µM) added at the end of each experiment.  
Acetaldehyde assay. Mouse Schwann cells and HSC were plated in 48-well plates 
in 5% CO2 and 95% O2 at 37°C until 90% of confluence. The cultured medium was 
replaced with PBS added with ethanol (1-100 mM), ethanol (10 mM) plus 4-Mp (100 
µM) or vehicle (0.9% NaCl) and maintained in 5% CO2 and 95% O2 at 37°C for 3 h. 
Then, supernatants were collected, and acetaldehyde content was assayed by using a 
colorimetric assay (Megazyme) according to the manufacturer’s protocol. Acetaldehyde 
content was expressed as µmol/l. The cytotoxicity to different stimuli was tested by using 
the MTT assay viability test. 
H2O2 assay. H2O2 was determined by the Amplex Red
® assay. HSC were plated in 
96-well clear bottom black (5x105 cells/well) and maintained in 5% CO2/95% O2 (24 h, 
37°C). The cultured medium was replaced with Krebs/HEPES added with A967079 (30 
µM) or vehicle (0.3% DMSO) for 10 min at room temperature. HSC were stimulated 
with AITC (100 µM), H2O2 (200 nM) and acetaldehyde (10 mM) or their vehicle (0.01% 
DMSO, Krebs/HEPES), added with Amplex red (50 µM) and HRP (1 U/ml, 30 min, 
room temperature, protected from light). Some experiments were performed in Ca2+-free 
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Krebs/HEPES buffer containing ethylenediaminetetraacetic acid (EDTA, 1 mM). Signal 
was detected 60 min after exposure to stimuli. H2O2 release was calculated using H2O2 
standards and expressed as nmol/l. 
 
Immunofluorescence 
Anesthetized mice were transcardially perfused with PBS and 4% 
paraformaldehyde. Paw tissues were removed, post-fixed for 24 h, and paraffin 
embedded. Human and mouse FFPE sections (5 µm) were incubated with primary 
antibodies (all from Abcam): TRPA1 (ab58844, rabbit polyclonal, 1:400), S100 
(ab14849, mouse monoclonal [4B3], 1:300), protein gene product 9.5 (PGP9.5, ab8189, 
mouse monoclonal [13C4/I3C4], 1:600), NOX1 (ab131088, rabbit polyclonal, 1:250), 4-
HNE (HNEJ-2, ab48506, mouse monoclonal, 1:40) and alcohol dehydrogenase 
(ab108203, rabbit monoclonal [EPR4439], 1:200) diluted in fresh blocking solution 
(PBS, pH 7.4, 2.5% NGS). To confirm specificity, TRPA1, NOX1 and ADH primary 
antibodies were pre-adsorbed (1:1, overnight, 4°C, before adding to tissue sections) with 
their respective antigen peptides: TRPA1 synthetic peptide (sequence: 
CEKQHELIKLIIQKME, Twin Helix srl); ADH recombinant protein, (#NBP1-99053, 
Novus Biologicals), NOX1 recombinant protein (#PCPKAB7187921P, Promocell). 
Sections were then incubated with the fluorescent polyclonal secondary antibodies, Alexa 
Fluor 488 and 594 (1:600, Invitrogen), and coverslipped using mounting medium with 
DAPI (Abcam). The product of the differences from the mean (PDM) image was used for 
the qualitative analysis of colocalization. The PDM image is a pseudo-colored, generated 
by pixel that is equal to the PDM value at the location (Image J, NIH).  
Human Schwann cells were grown on glass coated (poly-L-lysine, 8.3 µM) 
coverslips and cultured for 2-3 days before staining. Cells were fixed in ice-cold 
methanol/acetone (5 min at -20°C), washed with PBS and blocked with NGS (10%) (1 h, 
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room temperature). The cells were incubated with primary antibodies: TRPA1 (ab58844, 
rabbit polyclonal, 1:400), S100 (ab14849, mouse monoclonal [4B3], 1:300), NOX1 
(ab131088, rabbit polyclonal, 1:250) and alcohol dehydrogenase (ab108203, rabbit 
monoclonal [EPR4439], 1:200) diluted in fresh blocking solution (PBS, pH 7.4, 2.5% 
NGS). Cells were finally incubated with fluorescent polyclonal secondary antibodies 
(1:600, Alexa Fluor 488, and 594, Invitrogen) (2 h, room temperature) and mounted using 
mounting medium with DAPI (Abcam). Fluorescence images were obtained using an 
BX51 microscope (Olympus).  
 
Immunohistochemistry and intraepidermal nerve fiber (IENF) analysis 
Anesthetized mice were transcardially perfused with PBS and 4% 
paraformaldehyde. Mice paws were placed overnight at 4°C in 10% formalin, transferred 
to 30% sucrose overnight  and frozen and cryosectioned at 30 µm transversal to long paw 
axis. Free floating sections were incubated in PBS containing 0.1% Triton X-100 (TBS) 
and 2.5% NGS 1 hour at room temperature, then in the primary antibody panaxonal 
marker PGP9.5 (ab108986, rabbit monoclonal [EPR4118] 1:600, Abcam) overnight at 
room temperature. Afterward, sections were rinsed in TBS and placed in secondary 
biotinylated goat anti-rabbit IgG antibody (Vector Laboratories), 1:300, 2 hour at room 
temperature, placed in avidin-biotin complex solution (Vectastain Elite ABC HRP, 
Vector Laboratories) for 30 min at room temperature, followed by rinsing in TBS. The 
sections were then transferred into ImmPACT DAB (Vector Laboratories) to 4-6 min for 
the chromogen development reaction and rinsed in distilled water before mounting. IENF 
were counted either under microscope at 40X magnification. Single PGP9.5-positive 
fibers crossing the epidermis-dermis boundary (basal membrane) were counted. 
Secondary branching is excluded from quantification, according to the European 




RNA was extracted from paw tissue and liver obtained from C57BL/6J mice or 
from human Schwann cells. Total RNA was extracted using the RNeasy Mini kit (Qiagen 
SpA), according to the manufacturer’s protocol. RNA concentration and purity were 
assessed spectrophotometrically.  Reverse transcription was performed with the Qiagen 
QuantiTect Reverse Transcription Kit (Qiagen SpA) following the manufacturer's 
protocol. For mRNA relative quantification, rt-PCR was performed on Rotor Gene® Q 
(Qiagen SpA). The sets of probes for human cells were: ACTB (β-actin): Primer1 CCT 
TGC ACA TGC CGG AG Primer2 ACA GAG CCT CGC CTT TG Probe /56-FAM/TCA 
TCC ATG /ZEN/GTG AGC TGG CGG /3IABkFQ/ (NCBI Ref Seq: NM_001101); 
TRPA1: Primer1 GAA ACC AAA GTG GCA GCT TC Primer2 GAC ATT GCT GAG 
GTC CAG AA Probe /56-FAM/TGA AGT TCC /ZEN/ACC TGC ATA GCT ATC CTC 
T/3IABkFQ/ (NCBI Ref Seq: NM_007332); NOX1 Primer1 AAA CAT TCA GCC CTA 
ACC AAA C Primer2 GAA TCT TCC CTG TTG CCT AGA Probe /56-FAM/ACC ACC 
CAG /ZEN/TTT CCC ATT GTC AAG A/3IABkFQ/ (NCBI Ref Seq:NM013955); 
ADH1A: Primer1 GTT TCT TTA ACT CCC ATA GCA CAG Primer2 CAC AAG GAC 
TCA CCA GTC TC Probe /56-FAM/AGA CAG AAT /ZEN/CAA CAT GAG CAC AGC 
AGG /3IABkFQ/ (NCBI Ref Seq: NM_000667); ADH1B: Primer1 GTG CTC ATG TCG 
TTT CTG TCT Primer2 TCA AGC AGA GAA GAA ATC CAC AA Probe/56-
FAM/TGC CCA CCA /ZEN/GCA GAC TGT GA/3IABkFQ/ (NCBI Ref Seq: 
NM_000668), ADH1C: Primer1 ATC TTA ATG CGA ACT TCA TGA GC Primer2 
CAG AAT CAA TAT GAG CAC AGC AG Probe /56-FAM/CCA TTG AGG 
/ZEN/AGG TAG AGG TTG CAC C/3IABkFQ/ (NCBI Ref Seq: NM_000669); ADH4: 
Primer1 AGA AAG ACC CAC ACC TCC TA Primer2 GAG TTT GTC TGC TTG GAT 
GTG Probe /56-FAM/CCC TGG TTC /ZEN/GAC TTG TGC TGT CT/3IABkFQ/ (NCBI 
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Ref Seq: NM_000670); ADH5: Primer1 TGC CAC CTC TAT CTC CTC TAT G 
Primer2 CCG ACC AGA ATC CGT GAA C Probe /56-FAM/AGC CTT GCA 
/ZEN/CTT GAT AAC CTC GTT CG/3IABkFQ/ (NCBI Ref Seq: NM_000671); ADH6: 
Primer1 TGT GGC AGA AAG AGT GTG AT Primer2 CCT CTT GTA TCC CAC CAT 
CTT G Probe /56-FAM/TCA CCT GGT /ZEN/TTC ACT GTG CTT ACT 
CC/3IABkFQ/(NCBI Ref Seq: NM_000672). 
The sets of probes for mouse tissue were: ACTB: Primer1 GAC TCA TCG TAC 
TCC TGC TTG Primer2 GAT TAC TGC TCT GGC TCC TAG Probe /56-FAM/CTG 
GCC TCA /ZEN/CTG TCC ACC TTC C/3IABkFQ/ (NCBI Ref Seq: NM_001101); 
ADH1: Primer1 AAGACT ACAGCAAACCCATCC Primer2 GACGACGCTT 
ACACCACAT Probe /56-FAM/CCTTGACAC/Z EN/CA TGACTTCTGCCCT 
/31ABkFQ/ (NCBI Ref Seq: NM_007409); ADH5: Primer1 TCATCCCACTCT 
ACATCCCA Primer2 GGT AAATCTGCT AGTCCCATCT Probe /56-
FAM/CCCTTCCCC/Z EN/TGAGTGACCCTT A TTTTC/31ABkFQ/ (NCBI Ref Seq 
NM_007410); ADH7: Primer1 TGAAGTT ATTGGGCGTCTTGA Primer2 
GTCATAGGTGAGCATCTTGGC Probe /56-FAM/CAGTGTGGT /Z 
EN/GGTTGGTGCTCCT /31ABkFQ/ (NCBI Ref Seq NM_009626). 
The chosen reference gene was the ACTB. The QuantiTect Probe PCR Kits 
(Qiagen SpA) was used for amplification, and the cycling conditions were: samples were 
heated to 95°C for 10 min followed by 40 cycles of 95°C for 15 s, and 65°C for 20 s. 
PCR reaction was carried out in triplicate. Relative expression of mRNA was calculated 
using the 2-Δ(ΔCT) comparative method, with each gene normalized against ACTB gene for 
the same sample. 
 
Statistical analysis  
Statistical analysis was performed by the unpaired two-tailed Student’s t-test for 
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comparisons between two groups. Group means were compared with a one-way 
ANOVA, followed, as needed, by the pair-wise comparison of multiple groups that 
employed the Bonferroni’s correction to maintain the experiment-wise error rate at 5%. 
For behavioural experiments with repeated measures, a two-way mixed model was used 
to compare the control and treated groups of mice at each time point tested, using the 
Bonferroni’s correction for multiple time points.  Statistical analyses were performed on 
raw data using Prism 5 GraphPad software (GraphPad Software Inc.). P<0.05 was 
considered statistically significant. 
 
Study Approval  
The use of FFPE sections of human skin samples was approved by the Local Ethics 
Committee (#11989_bio/2018), according to the Helsinki Declaration, and informed 
consent was obtained. All applicable international, national, and/or institutional 
guidelines for the care and use of animals were followed. In vivo experiments were in 
accordance to European Union (EU) guidelines and Italian legislation (DLgs 26/2014, 
EU Directive application 2010/63/EU) for animal care procedures, and under the 
University of Florence research permit #194/2015-PR. Animal studies were reported in 
compliance with the ARRIVE guidelines (51). 
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Figure 1. TRPV1 mediates acute nociception and TRPA1 mediates allodynia 
evoked by local ethanol. (A) Dose-dependent acute nociception and (B) dose- and time-
dependent mechanical allodynia evoked by intraplantar (i.pl., 20 µl) ethanol (EtOH) or 
vehicle (Veh) in C57BL/6J mice. (C) Acute nociceptive response evoked by EtOH (30%, 
i.pl.) or Veh in Trpv1+/+ and Trpv1-/- mice. (D) Time-dependent mechanical allodynia 
evoked by EtOH (30%, i.pl.) or Veh in Trpv1+/+ and Trpv1-/- mice. (E and F) Time-
dependent mechanical allodynia evoked by EtOH (30%, i.pl.) or Veh in C57BL/6J mice 
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pretreated with 4-methylpyrazole (4-Mp, 50 mg/kg, intragastric, i.g., or 100 µg, i.pl.) or 
Veh 4-Mp. (G) Acute nociceptive response and (H) time-dependent mechanical allodynia 
evoked by EtOH (30%, i.pl.) or Veh in Trpa1+/+ and Trpa1-/- mice. (I) Dose-dependent 
acute nociceptive response and (J) dose- and time-dependent mechanical allodynia 
evoked by acetaldehyde (ACD, 1-20 nmol, i.pl.) or Veh in C57BL/6J mice. (K and L) 
Acute nociceptive response and time-dependent mechanical allodynia evoked by ACD 
(20 nmol, i.pl.) or Veh in Trpa1+/+ and Trpa1-/- mice. BL, baseline. Veh is the vehicle of 
EtOH or ACD. (A, C, G, I and K) box plots with horizontal lines at the 25th percentile, 
the median, and the 75th percentile and the vertical lines which extend to the minimum 
and maximum values; (B, D, E, F, H, J and L) mean ± SEM with individual data points 
overlaid; n=8 mice for each experiment. *P<0.05, **P<0.01, ***P<0.001 vs. Veh, Veh-
Trpv1+/+ and Veh-Trpa1+/+; §P<0.05, §§§P<0.001 vs. EtOH, EtOH-Trpv1+/+, EtOH-
Trpa1+/+, ACD and ACD-Trpa1+/+; one-way (A, C, G, I and K) or two-way (B, D, E, F, 





Figure 2. TRPA1 mediates mechanical allodynia evoked by intragastric 
ethanol in C57BL/6J mice hind paw. (A) Dose-dependent mechanical allodynia evoked 
by ethanol (EtOH, intragastric, i.g.) or vehicle (Veh). (B) Time-dependent mechanical 
allodynia evoked by EtOH (15%, 4 ml/kg, i.g.) or Veh in Trpa1+/+ and Trpa1-/- mice. (C 
and D) Mechanical allodynia evoked by EtOH (15%, 4 ml/kg, i.g.) or Veh after A967079 
(A96, 100 mg/kg, intraperitoneal, i.p. or 100 µg/site, intraplantar, i.pl.) or Veh A96 in 
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C57BL/6J mice.  (E) Time course of EtOH levels in plasma and liver and hind paw 
tissue, after EtOH (15%, 4 ml/kg, i.g.) in C57BL/6J mice. (F) Time-dependent 
mechanical allodynia evoked by EtOH (15%, 4 ml/kg, i.g.) or Veh in C57BL/6J mice 
pretreated with 4-methylpyrazole (4-Mp, 50 mg/kg, i.g.) or Veh 4-Mp. BL, baseline. Veh 
is the vehicle of EtOH. Data are mean ± SEM with individual data points overlaid; n=8 
mice for each experimental condition. *P<0.05, **P<0.01, ***P<0.001 vs. Veh and 
EtOH BL; §§§P<0.001 vs.  EtOH-Trpa1+/+, EtOH-A96 and 4-Mp-EtOH; one-way (E) or 





Figure 3. Acetaldehyde is generated by both hepatic and Schwann cell alcohol 
dehydrogenase. (A) Alcohol dehydrogenase (ADH) 1, 5 and 7 (ADH1, ADH5 and 
ADH7) mRNA relative expression in hind paw tissue in C57BL/6J mice. (B and C) 
Representative images of ADH, S100 and PGP9.5 expression in hind paw tissue in 
C57BL/6J mice. (D) Dose-dependent acetaldehyde (ACD) levels in cultured Schwann 
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cells isolated from C57BL/6J mice and exposed to ethanol (EtOH, 1-100 mM) in the 
presence of 4-methylpyrazole (4-Mp, 100 µM) or vehicle (Veh 4-Mp). (E) Time-
dependent ACD levels (hind paw tissue) after intraplantar, (i.pl., 20 µl) EtOH (30%) in 
C57BL/6J mice. (F) ACD levels (hind paw tissue) of C57BL/6J mice receiving EtOH 
(30%, i.pl.) or Veh and pretreated with 4-Mp (100 µg, i.pl.) or Veh 4-Mp. (G and H) 
Time-dependent mechanical allodynia and ACD levels (hind paw tissue) in C57BL/6J 
mice receiving EtOH (15%, 4 ml/kg, intragastric, i.g.) or Veh and pretreated with 4-Mp 
(100 µg, i.pl. or 50 mg/kg, i.g.) or Veh 4-Mp. BL, baseline. Veh is the vehicle of EtOH. 
[In] and [Out] indicate inside and outside, respectively, the perineurium, delimited by 
dashed lines. (D, F and H) box plots with horizontal lines at the 25th percentile, the 
median, and the 75th percentile and the vertical lines which extend to the minimum and 
maximum values; (A, E and G) mean ± SEM with individual data points overlaid; n=6-8 
mice for each experimental condition. *P<0.05, ***P<0.001 vs. Veh and ACD BL; 
§P<0.05, §§§P<0.001 vs.  EtOH and EtOH-4-Mp; one-way (D-F, and H) or two-way (G) 




Figure 4. Acetaldehyde via TRPA1 sustains ethanol-evoked allodynia in 
C57BL/6J mice hind paw. (A) Dose- and time-dependent mechanical allodynia evoked 
by acetaldehyde (ACD, intraperitoneal, i.p.) or vehicle (Veh). (B) Time-dependent 
mechanical allodynia evoked by ACD (0.1 mg/kg, i.p.) or Veh in Trpa1+/+ and Trpa1-/- 
mice. (C and D) Mechanical allodynia evoked by ACD (0.1 mg/kg, i.p.) or Veh after 
A967079 (A96, 100 mg/kg, i.p. or 100 µg, intraplantar, i.pl.) or  Veh A96 in C57BL/6J 
mice. (E) Time dependent ACD levels in liver and hind paw tissue after ethanol (EtOH, 
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15%, 4 ml/kg, intragastric, i.g.) in C57BL/6J mice. (F) Effect of post treatment with 4-
methylpyrazole (4-Mp, 50 mg/kg, i.g.) or Veh 4-Mp on mechanical allodynia evoked by 
EtOH (15%, 4 ml/kg, i.g.) or Veh, in C57BL/6J mice. (G and H) Mechanical allodynia 
evoked by EtOH (30%, i.pl. and 15%, 4ml/kg, i.g.) Veh after phenyl-α-tert-butyl nitrone 
(PBN, 100 µg, i.pl. or 50 mg/kg, i.p.) or Veh PBN  in C57BL/6J mice. (I and J) 
Mechanical allodynia evoked by ACD (10 nmol, i.pl. and 0.1 mg/kg, i.p.) or Veh after 
PBN (100 µg, i.pl. or 50 mg/kg, i.p.) or Veh PBN in C57BL/6J mice. BL, baseline. Veh 
is the vehicle of EtOH and ACD. Data are mean ± SEM with individual data points 
overlaid; n=6-8 mice for each experimental condition. *P<0.05, ***P<0.001 vs. Veh and 
ACD BL; §§§P<0.001 vs. ACD-Trpa1+/+, ACD-A96, EtOH-PBN and ACD-PBN; one-




Figure 5. Acetaldehyde via TRPA1 generates ROS that sustain ethanol-evoked 
allodynia. (A) H2O2 levels (hind paw) after ethanol (EtOH, intragastric, i.g. or  
intraplantar, i.pl.). (B) 4-hydroxynonenal (4-HNE) staining (plantar nerve) and levels 
(hind paw) after i.g. EtOH (C) Mechanical allodynia evoked by EtOH i.g. or vehicle 
(Veh) after N-acetyl cysteine (NAC, 250 mg/kg, intraperitoneal, i.p.) and phenyl-α-tert-
butyl nitrone (PBN, 50 mg/kg, i.p.) or their Veh. H2O2 levels (hind paw) after i.g. and i.pl. 
EtOH or Veh in mice pretreated with (D) 4-methylpyrazole (4-Mp, 50 mg/kg, i.g.), (E) 
A967079 (A96, 100 mg/kg, i.p.) and PBN (100 mg/kg, i.p.) or their Veh. (F)  H2O2 levels  
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(hind paw) after acetaldehyde (ACD, 0.1 mg/kg, i.p. or 10 nmol, i.pl.). (G) H2O2 levels 
(hind paw tissue) after ACD (0.1 mg/kg, i.p. or 10 nmol, i.pl.) or Veh and pretreated with 
A96 (100 mg/kg, i.p.) or PBN (100 mg/kg, i.p.) or their Veh . (H) H2O2 levels (hind paw) 
in Trpa1+/+ and Trpa1-/- mice treated with (H) i.g. and i.pl. EtOH, (I)  ACD (0.1 mg/kg 
i.p. and 10 nmol, i.pl.) or their Veh. BL, baseline. Veh is the vehicle of EtOH and ACD. 
Where not indicated mice are C57BL/6J and EtOH doses are: i.g., 15%,  4 ml/kg and 
i.pl.  30%, 20 µl. (B, 4-HNE mean grey value) box plots with horizontal lines at the 25th 
percentile, the median, and the 75th percentile and the vertical lines which extend to the 
minimum and maximum values; all other data are mean ± SEM with individual data 
points overlaid; n=6-8 mice for each experimental condition. *P<0.05, **P<0.01, 
***P<0.001 vs. Veh, ACD-BL and H2O2-BL; 
§P<0.05, §§§P<0.001 vs. EtOH, EtOH-A96, 
EtOH-PBN, EtOH-Trpa1+/+, ACD-A96, ACD-PBN and ACD-Trpa1+/+; one-way (A, B 




Figure 6. Schwann cell TRPA1 contributes to oxidative stress generation. (A 
and B) Representative images of NADPH oxidase 1 (NOX1), S100  and TRPA1 
expression in plantar nerve of C57BL/6J mice. (C) Mechanical allodynia evoked by 
ethanol (EtOH, 15%, 4 ml/kg, intragastric, i.g.) and acetaldehyde (ACD, 0.1 mg/kg, 
intraperitoneal, i.p.) or their vehicle (Veh) after ML171 (100 mg/kg, i.p.) or Veh ML171  
in C57BL/6J mice. (D) Time-dependent mechanical allodynia evoked by EtOH (30%, 
intraplantar, i.pl. and 15%, 4 ml/kg, i.g.)  or Veh in Plp-CreERT;Trpa1fl/fl and Control 
mice. (E) H2O2 levels (hind paw) after EtOH (30%, i.pl. and 15%, 4 ml/kg i.g.) or Veh in 
Plp-CreERT;Trpa1fl/fl and Control mice. (F) Time dependent mechanical allodynia evoked 
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by EtOH (30%, i.pl. and 15%, 4 ml/kg, i.g.) or Veh in Adv-Cre;Trpa1fl/fl and Control 
mice. (G) H2O2 levels (hind paw tissue) after EtOH (30%, i.pl. and 15%, 4 ml/kg, i.g.) or 
Veh in Adv-Cre;Trpa1fl/fl and Control mice. BL, baseline. Veh is the vehicle of EtOH and 
ACD. Dashed lines indicate perineurium. Data are mean ± SEM with individual data 
points overlaid; n=6-8 mice for each experimental condition. **P<0.01, ***P<0.001 vs. 
Veh; §§P<0.01, §§§P<0.001 vs. EtOH i.g. or EtOH i.pl. control; one-way (E and G) or 




Figure 7. Schwann cell TRPA1 mediates mechanical allodynia evoked by 
chronic ethanol treatment. (A) Overview of the experimental design of the chronic 
ethanol (EtOH) feeding model. (B) Time-dependent mechanical allodynia by EtOH- (5% 
(vol/vol) for 28 days, EtOH-fed) or control (pair-fed)-diet in Trpa1+/+ and Trpa1-/- mice 
and Plp-CreERT;Trpa1fl/fl and Control mice. (C) Mechanical allodynia evoked by EtOH- 
or control-diet at day 28 after A967079 (A96, 100 mg/kg, intraperitoneal, i.p.) and 
phenyl-α-tert-butyl nitrone (PBN, 100 mg/kg, i.p.) or their Veh in C57BL/6J mice. (D) 
Representative photomicrographs and cumulative data of  4-hydroxynonenal (4-HNE) 
staining (plantar nerve) and levels (hind paw), and H2O2 levels (hind paw) in Trpa1
+/+ 
and Trpa1-/- mice and Plp-CreERT;Trpa1fl/fl and Control mice at day 28 after EtOH- or 
control-diet. (E) Representative photomicrograph of PGP9.5 staining and cumulative data 
of intraepidermal nerve fiber (IENF) density in the paw of Trpa1+/+ and Trpa1-/- mice and 
Plp-CreERT;Trpa1fl/fl and Control mice at day 28 after EtOH- or control-diet. BL, 
baseline. (D, 4-HNE-His and E) box plots with horizontal lines at the 25th percentile, the 
median, and the 75th percentile and the vertical lines which extend to the minimum and 
maximum values; all other data are mean ± SEM with individual data points overlaid; 
n=8 mice for each experimental condition. *P<0.05, ***P<0.001 vs. pair-fed Trpa1+/+, 
pair-fed control or EtOH-fed Veh A96/A96 day 0; §P<0.05, §§P<0.01, §§§P<0.001 vs. 
EtOH-fed Trpa1+/+, EtOH-fed control or EtOH-fed Veh A96; unpaired two-tailed 
Student’s t-test (D mean grey value), one-way (D 4-HNE-His adducts and H2O2, and E) 




Figure 8. TRPA1 and alcohol dehydrogenase are present in human Schwann 
cells. Representative images of (A and B) S100 and alcohol dehydrogenase (ADH) 
expression, (E and F) TRPA1 and (J and K)  NOX1 immunofluorescence in cultured 
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human Schwann cells (HSC) and human skin. (C) ADH1A, ADH1B, ADH1C, ADH4, 
ADH5 and ADH7 mRNA relative expression in HSC. (D) Dose-dependent acetaldehyde 
(ACD) levels in HSC exposed to ethanol (EtOH, 1-100 mM) and treated with 4-
methylpyrazole (4-Mp, 100 µM). (G) TRPA1 mRNA expression in HSC relative to 
human TRPA1-HEK293 cells. (H) Intracellular calcium ([Ca2+]i) response to allyl 
isothiocyanate (AITC, 100 µM), H2O2 (10 mM) and ACD (10 mM) in HSC in the 
presence of A967079 (A96, 30 µM) or its vehicle (Veh). (I) [Ca2+]i response to EtOH (10 
mM) in HSC in the presence of A96 (30 µM), 4-Mp (100 µM) or their Veh. (L) NOX1 
mRNA expression in HSC relative to A549 cells. (M) H2O2 release evoked by AITC (100 
µM), H2O2 (200 nM) and ACD (10 mM) in HSC in the presence of A96 (30 µM), Veh or 
in Ca2+ free medium. Veh is the vehicle of EtOH, AITC, H2O2 and ACD. (C, D, G, L and 
M) box plots with horizontal lines at the 25th percentile, the median, and the 75th 
percentile and the vertical lines which extend to the minimum and maximum values; n=3 
replicates from 2 independent experiments in C, G and L and n=8 replicates from 3 
independent experiments in D and M; (H and I) data are mean ± SEM with individual 
data points overlaid, 41 to 327 cells n=3 to 5 experiments. *P<0.05, ***P<0.001 vs. Veh; 
§P<0.05, §§§P<0.001 vs. EtOH (10 mM), AITC (100 µM), H2O2 (200 nM) and ACD (10 
mM); (D, H, I and M) one-way ANOVA with Bonferroni post-hoc correction. 
 
 
